DDInter1782 DDInter1376
Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Tetracosactide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Racepinephrine
Tetracosactide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Salmeterol
Tetracosactide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentobarbital
Tetracosactide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Tetracosactide {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Tetracosactide {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Racepinephrine
Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Salmeterol
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Tetracosactide may lead to a major life threatening interaction when taken with Etanercept
Tetracosactide may lead to a major life threatening interaction when taken with Fingolimod